Online citations, reference lists, and bibliographies.
← Back to Search

A Randomised Double-blind Trial Of Cyclosporin And Azathioprine In Refractory Rheumatoid Arthritis.

M. Ahern, W. Harrison, P. Hollingsworth, J. Bradley, B. Laing, C. Bayliss
Published 1991 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Fifty-two patients with severe rheumatoid arthritis (RA) from four Australian centres were randomised to receive cyclosporin A (CSA) (n = 25) or azathioprine (AZA) (n = 27) for six months. Initial mean doses of CSA and AZA were 4.2 mg/kg and 1.7 mg/kg respectively. The mean doses of CSA and AZA at six months were 3.4 mg/kg and 1.9 mg/kg. Assessments of side-effects and outcomes of benefit were made monthly by independent, blinded observers. Both treatment groups exhibited statistically significant improvement in standard outcome parameters when compared with baseline values. However, there were no statistically significant differences in these parameters between the two groups. There was a mean increase in serum creatinine concentration associated with CSA; no persons were withdrawn from the study for this reason. Seven CSA recipients (three gastrointestinal symptoms, two neurological symptoms, two other) and 12 AZA recipients (six gastrointestinal symptoms, four inefficacy, two other) withdrew from treatment prematurely. Seven CSA recipients became hypertensive and four required anti-hypertensive therapy. Adverse events not requiring cessation of therapy were more commonly seen among CSA patients. In this group of severely affected patients with RA both cyclosporin and azathioprine were effective therapies. CSA toxicities were predictable and manageable but required close monitoring.
This paper references
10.1016/0002-9343(84)90356-5
Side effects of systemic cyclosporine in patients not undergoing transplantation.
A. Palestine (1984)
10.1016/0140-6736(90)92630-Z
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis
P. Tugwell (1990)
10.1080/01971528108062989
A radioimmunoassay to measure cyclosporin A in plasma and serum samples.
P. Donatsch (1981)
Remodelling the pyramid: the therapeutic target of rheumatoid arthritis.
W. Bensen (1990)
10.1002/ART.1780300102
Cyclosporin A treatment of refractory rheumatoid arthritis.
M. Weinblatt (1987)
10.1001/ARCHINTE.1990.00390140036008
Cyclosporine-Associated Hypertension
G. A. Porter (1990)
10.1136/ard.45.9.726
Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.
A. W. van Rijthoven (1986)
10.1136/ard.47.2.127
Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.
M. Dougados (1988)
10.1002/ART.1780300112
An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report.
O. Førre (1987)
Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies.
C. Lavalle (1990)
10.1038/KI.1986.125
Side effects of cyclosporin A treatment in patients with rheumatoid arthritis.
K. Berg (1986)
10.3109/03009747309098820
Evaluation of a functional index in rheumatoid arthritis.
P. Lee (1973)
Low dose cyclosporine in rheumatoid arthritis: a pilot study.
P. Tugwell (1987)
10.1002/ART.1780300111
Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial.
M. Dougados (1987)
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
J. Fries (1982)
10.1001/ARCHINTE.150.2.280
Cyclosporine-associated hypertension. National High Blood Pressure Education Program.
G. A. Porter (1990)
10.1016/S0378-4347(00)81500-5
High-performance liquid chromatographic determination of cyclosporin A in human plasma and urine.
W. Niederberger (1980)
10.1136/bmj.3.5934.763
Comparison of Azathioprine, Cyclophosphamide, and Gold in Treatment of Rheumatoid Arthritis
H. Currey (1974)



This paper is referenced by
10.3109/9780203427767
Practical Prescribing Guidelines for Rheumatoid Arthritis
H. Capell (2003)
10.1002/art.1780390502
[Guidelines for the management of rheumatoid arthritis].
Y. Kawahito (2016)
10.1016/S0950-3579(05)80310-3
Cyclosporin, leflunomide and nitrogen mustard
D. Furst (1995)
10.13181/MJI.V11I3.66
Comparative study of azathioprine and cyclosporin in rheumatoid arthritis – a sixteen weeks follow-up study
R. Aggarwal (2002)
10.1016/J.RDC.2004.08.002
Clinical trials in rheumatic diseases: designs and limitations.
T. Pincus (2004)
10.1136/ard.2007.071415
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
D. Aletaha (2008)
10.1016/S0049-0172(99)80035-3
T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis.
D. Yocum (1999)
10.1093/RHEUMATOLOGY/KEH565
Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria.
G. Kingsley (2005)
10.14412/1996-7012-2009-556
Циклоспорин а при ревматоидном артрите: современные данные
Елена Львовна Лучихина (2009)
10.2147/PGPM.S5012
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies
D. O’Rielly (2010)
10.2147/OPTH.S181811
Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
M. Nebbioso (2019)
10.1007/s12016-016-8582-3
The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review
C. Chighizola (2016)
10.1016/b978-1-4160-4673-8.10007-5
Drug-Induced Ocular Side Effects
F. Fraunfelder (1996)
10.1186/1745-6215-9-6
Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial
R. Rajendram (2008)
10.1016/S2213-8587(18)30021-4
Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
R. Rajendram (2018)
Guidelines for the Management of Rheumatoid Arthritis
L. G. Anderson (2002)
10.1038/KI.1996.415
Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy.
W. Bennett (1996)
10.1111/J.1445-5994.1993.TB01816.X
The use of suppressive agents for the treatment of rheumatoid arthritis.
P. Brooks (1993)
10.1007/BF02659091
Cyclosporin a in rheumatoid arthritis: A critical review
K. Khawar (2007)
10.1007/BF03259056
Category III Symptom-Modifying Antirheumatic Drugs
Dr Michael J. Ahern (2012)
10.3109/03602532.2015.1047027
Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases
R. Chaudhary (2015)
10.1111/J.1745-7599.2002.TB00072.X
Guidelines for the management of rheumatoid arthritis: 2002 update.
Grace Newsome (2002)
OPTH_A_181811 1147..1155
Marcella Nebbioso (2019)
10.1016/S0889-857X(05)70021-1
The use of Neoral in rheumatoid arthritis.
A. Cranney (1998)
10.1046/J.1523-1755.1998.00017.X
A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases.
S. Vercauteren (1998)
10.1002/ART.10148
Guidelines for the management of rheumatoid arthritis: 2002 Update.
R. Yood (2002)
10.1016/J.CLINTHERA.2007.06.016
Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
A. Gibofsky (2007)
10.1136/ard.2005.038513
Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
D. Aletaha (2006)
Semantic Scholar Logo Some data provided by SemanticScholar